LV12888B - 3-(pie slāpekļa atoma aizvietoti)fenil-5-beta-amidometiloksazolidin-2-oni - Google Patents

3-(pie slāpekļa atoma aizvietoti)fenil-5-beta-amidometiloksazolidin-2-oni Download PDF

Info

Publication number
LV12888B
LV12888B LVP-02-104A LV020104A LV12888B LV 12888 B LV12888 B LV 12888B LV 020104 A LV020104 A LV 020104A LV 12888 B LV12888 B LV 12888B
Authority
LV
Latvia
Prior art keywords
alkyl
defined above
optionally substituted
oxazolidin
taken together
Prior art date
Application number
LVP-02-104A
Other languages
English (en)
Inventor
Steven L. Brickner
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of LV12888B publication Critical patent/LV12888B/lv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Claims (6)

  1. LV 12888 IZGUDROJUMA FORMULA 3-(Pie slāpekļa atoma aizvietots)fenil-53-(amidometil)oksazolidin-2-ons ar formulu (LV)
    4 kur (I) Rļ ir-H, Cļ-C^alkilgrupa, kas neobligāti ir aizvietota ar 1-3 Cl atomiem, C3-C12cikloalkilgrupa, C5-C12alkenilgrupa, kas satur vienu dubultsaiti, -<ļ>, kas neobligāti ir aizvietots ar 1-3 grupām, kas ir izvēlētas no
    -N(R1.1)(R1.2), kur R,.! un R1.2 ir vienādi vai atšķirīgi un ir -H vai Cļ-C^alkilgrupa, furanilgrupa, tetrah id rof u ran i Ig ru pa, 2-tiofēngrupa, pirolidinilgrupa, piridinilgrupa, -0-R,.3, kur R1-3 ir Cļ-C^alkilgrupa, -NHRļ.3, kur R^ ir, kā noteikts iepriekš, -NR^R^, kur R1-4 ir C1-C3alkilgrupa un R^ ir, kā noteikts iepriekš, un kur R,.3 un R,.4 var tikt ņemti kopā ar pievienoto slāpekļa atomu, lai veidotu piesātinātu C5-C7 heterociklisku gredzenu ar vienu slāpekļa atomu, kas ietver -0-, -CH2-OH, 2 -CHpRļ.g, kur R,_5 ir Cļ-C^alkilgrupa vai -CO-Rļ.g, kur R^ ir CrC4alkilgrupa vai -φ; (II) divi no R2, R3 un R4 ir -H un citi no R2, R3 un R4 ir -H, 5 -F, -Cl, -Br, -I, Cļ-Cgalkilgrupa, -OH, -CO-O-R^, kur R^ ir CrC4alkilgrupa vai -φ, 10 -O-R^, kur R2_i ir, kā noteikts iepriekš, -COOH, -COO, -CHO, -CO-NR2.2R2.3, kur R2.2 un R2.3 ir vienādi vai atšķirīgi un ir -H, 15 Cļ-C^alkilgrupa vai R2.2 un R2.3 ir ņemti kopā ar pievienoto slāpekļa atomu, lai veidotu piesātinātu C3-C6heterociklisku gredzenu ar vienu slāpekļa atomu, kas neobligāti satur -0-, -C=N, -OCH, 20 -N=C, -CHOH-CH3, -CO-CH3, -SH, -SO-CH3,
  2. 25 -SO-φ, -s-ch3, -S-φ, -S02-CH3, -302-φ, 30 -S03H, -so2-nh2, -n3, -no2, 3 LV 12888 -NR2.4R2.5, kur R2.4 un R2.5 ir vienādi vai atšķirīgi un ir -H un Cļ-Caalkilgrupa, -NH-CO-R2.6, kur R2.6 ir Cļ-C^alkilgrupa vai -φ, -NH-CO-NH2, -ch=ch2, -ch2-ch=ch2, -CH=N-OH, -CH=N-OCH3, -ch3-c=n-oh, I -CH3-C=N-OCH3i I -C*H-CH2-0*, kur atomi, kas ir iezīmēti ar zvaigznīti (*), ir piesaistīti viens otram, rezultātā veidojot ciklu, (INA) kur W, un W2 ņemti kopā ir (XXXII), -nr5-n=cr6- kur R5 ir C^Cļgalkilgrupa, -ΟΗ2-φ, -ΟΗ2ΟΗ2-φ, C3-C7cikloalkilgrupa, C2-C12alkenilgrupa, kas satur no 1 līdz 3 dubultsaitēm ieskaitot, C2-C12alkinilgrupa, kas satur 1 trīskāršo saiti, -CHO, -CO-R^, kur R^ ir (A) CrC6alkilgrupa, kas neobligāti ir aizvietota ar 1 -0-CH3, -COOH, -NH2, -S03H vai 1-3 -Cl, (B) C3-C7cikloalkilgrupa, (C) 2-piridinilgrupa, 2-tiofēngrupa, 2-tiofēnmetilgrupa vai 2-pirolgrupa, 4 (D) -<ļ>, kas neobligāti ir aizvietots ar 1-3 -F, -Cl, -Br, -I, CVCgalkilgrupām, -OH, -C0-0-R5.2, kur R5.2 ir C^C^Ikilgrupa vai -φ, -0-R5.2, kur R5_2 ir, kā noteikts iepriekš, -COOH, -CO-NR5.3R5.4, kur R5_3 un R5_4 ir vienādi vai atšķirīgi un ir -H, C1-C3alkilgrupa, vai R5_3 un R5.4 ir ņemti kopā ar pievienoto slāpekļa atomu, lai veidotu piesātinātu C3-C6heterociklisku gredzenu ar vienu slāpekļa atomu, kas neobligāti satur -O-, -C=N, -CHOH-CH3, -CO-CH3, -SH, -SO-CH3, -SO-φ, -s-ch3, -S-Φ, -S02-CH3, -302-φ, -so3h, -so2-nh2, -n3, -no2, -NRs_5R5.6, kur R5.5 un R5.6 ir vienādi vai atšķirīgi un ir -H un Cļ-Cgalkilgrupa, -NH-CO-R5.7, kur R5.7 ir CrC4alkilgrupa vai -φ, -C0-0-R5.8, kur R5.8 ir C1-C4alkilgrupa vai -φ, katrs neobligāti ir aizvietots ar 1 vai 2 5 LV 12888 -F, -Cl, -Br, -I, Cļ-Cgalkilgrupām, -OH, -C0-0-R5.2, kur R5.2 ir, kā noteikts iepriekš, -0-R5.2, kur R5.2 ir, kā noteikts iepriekš, -COOH, -CO-NR5.3R5_4, kur R5.3 un R5.4 ir, kā noteikts iepriekš, -CsN, -CHOH-CHj, -CO-CH3, -SH, -SO-CH3, -SO-φ, -S-CH3, -S-φ, -S02-CH3, -802-φ, -so3h, -so2-nh2, -n3, -no2, -NR5.5Rs.6, kur R5.5 un R5.6 ir, kā noteikts iepriekš, -NH-CO-R5.7, kur R5.7 ir, kā noteikts iepriekš, -CO-N(R5.9)2, kur R5.9 ir -H vai R5.8, kā noteikts iepriekš, un kur R5.9 atlikumi var tikt ņemti kopā ar pievienoto slāpekļa atomu, lai veidotu piesātinātu C3-C6heterociklisku gredzenu ar vienu slāpekļa atomu, kas neobligāti satur -0- vai -NH-, -CO-CH2-CN, -co-ch2-oh, -00-ΟΗ2-0-φ, ku^ neobligāti ir aizvietots ar 1-3 -0-CH3, 1 -N02 un 1 -NH2, -CO-CH2-O-R5.10, kur R5.10 ir CrC6alkilgrupa, 6 -φ, kas neobligāti ir aizvietots ar 1 -3 -0-CH3, 1 -N02 un -NHZ, -CO-Rg.^, kur Rg.^ ir Cv-Cgalkilgrupa, -φ, kas neobligāti ir aizvietots ar 1-4 -F, 1-3 -Cl, 1 -OCH3, -OH, -NH2, -N02, -CO-CH3, -S02-CH3 un -S02-0H, -CO-CH(NH-CO-R5.12)-R5.13, kur R5.13 ir -H vai -CR3 un R5.12 ir CrC6alkilgrupa, -φ, kas neobligāti ir aizvietots ar 1 vai 2 -OH, -OCH3, -N02i -NH2i -Cl, -F, -NH-CH3 un -N(CH3)2, -CO-CHNH2-R5.14, kur R5.14 ir -CH(CH3)2, -CH2-CH(CH3)2, -CHCH3-CH2-CH3, -CH2-OH, CH(OH)-CH3, -ΟΗ2-φ, -ΟΗ2-φ-ΟΗ, -CH2-SH, -CH2-CH2-S-CH3 un -CH2-COOH, -S02-CH3, -so2-b, -so3h un R6 ir -H un Cļ-Cgalkilgrupa; vai (IIIB), kur W, un W2 ņemti kopā ir -NR5-N=N- (LIV), kur Rg ir, kā noteikts iepriekš; un tā farmaceitiski pieņemami sāļi. Savienojums saskaņā ar 1. punktu, kur Wļ un W2 ņemti kopā ir -NR5-N=CR6-. Savienojums saskaņā ar 1. punktu, kur Wļ un W2 ņemti kopā ir -NRS-N=N-. Savienojums saskaņā ar jebkuru no iepriekšējiem punktiem, kur R2, R3 un R4 visi ir H. 7 LV 12888
  3. 5. Savienojums saskaņā ar jebkuru no iepriekšējiem punktiem, kur R, ir H, CrC6alkilgrupa, C3-C6cikloalkilgrupa, -OCH3 vai -CHCĻ un R5 ir izvēlēts no -CH3, -CH2-CH=CH2, -CH2-C=CH, -CHO un -CO-Rg., kur Rs., ir -CH3, -C2H5, -CH(CH3)2, -CHCĻ -CH2OH, -CH2-0-CH3, 2-tiofenilgrupa vai cik-5 lopentilgrupa.
  4. 6. Savienojums saskaņā ar 2. punktu, kurš ir 3-[5’-(1-acetilindazolil)]-5P-(acetamidometil)oksazolidin-2-ons, 3-(5’-indazolil)^-(acetamidometil)oksazolidin-2-ons, 10 3-[5’-(1 -etilindazolil)]-53-(acetamidometil)oksazolidin-2-ons vai 3-[5’-(1-n-propilindazolil)]-5p-(acetamidometil)oksazolidin-2-ons.
  5. 7. Savienojuma saskaņā ar jebkuru no iepriekšējiem punktiem izmantošana ārstniecības līdzekļa ražošanai izmantošanai gram-pozitīvu vai anaerobu 15 organismu izraisītu infekciju ārstēšanā.
  6. 8. Savienojums saskaņā ar jebkuru no 1. punkta līdz 4. punktam, izņemot to, ka Rs ir H.
LVP-02-104A 1988-09-15 2002-06-06 3-(pie slāpekļa atoma aizvietoti)fenil-5-beta-amidometiloksazolidin-2-oni LV12888B (lv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24498888A 1988-09-15 1988-09-15
US25385088A 1988-10-05 1988-10-05
US32494289A 1989-03-17 1989-03-17

Publications (1)

Publication Number Publication Date
LV12888B true LV12888B (lv) 2002-12-20

Family

ID=27399816

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-02-104A LV12888B (lv) 1988-09-15 2002-06-06 3-(pie slāpekļa atoma aizvietoti)fenil-5-beta-amidometiloksazolidin-2-oni

Country Status (14)

Country Link
EP (3) EP0609905B1 (lv)
JP (2) JP2865211B2 (lv)
KR (1) KR0138262B1 (lv)
AT (2) ATE201870T1 (lv)
AU (1) AU617871B2 (lv)
CA (1) CA1335103C (lv)
DE (2) DE68918792T2 (lv)
DK (2) DK175696B1 (lv)
ES (1) ES2157934T3 (lv)
GR (1) GR3036491T3 (lv)
HK (1) HK1002234A1 (lv)
LV (1) LV12888B (lv)
TW (1) TW219936B (lv)
WO (1) WO1990002744A1 (lv)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
ATE204275T1 (de) * 1990-06-07 2001-09-15 Astrazeneca Ab Indolderivate als 5-ht1-like agonisten
CZ283323B6 (cs) * 1991-08-14 1998-02-18 Procter And Gamble Pharmaceuticals, Inc. Cyklické urethany použitelné jako antiarytmická a antifibrilační činidla a farmaceutické přípravky, které je obsahují
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
AU666740B2 (en) * 1992-07-08 1996-02-22 Upjohn Company, The 5'-indolinyl oxazolidinones useful against (mycobacterium tuberculosis)
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE19514313A1 (de) * 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
CZ291847B6 (cs) * 1994-10-26 2003-06-18 Pharmacia Upjohn Company Antimikrobiální fenyloxazolidinony
RU2128660C1 (ru) * 1994-11-15 1999-04-10 Фармация Энд Апджон Компани Бициклические оксазин- или тиазин-оксазолидиноны или их фармацевтически приемлемые соли и способы лечения микробных инфекций
PL185872B1 (pl) * 1995-02-03 2003-08-29 Upjohn Co Nowe podstawione fenylooksazolidynonyNowe podstawione fenylooksazolidynony
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
DE69614847T2 (de) * 1995-05-11 2002-04-04 Pharmacia & Upjohn Co., Kalamazoo Spirocyclische und bicyclische diazinyl- und carbazinyloxazolidinone
US5883093A (en) * 1995-09-12 1999-03-16 Pharmacia & Upjohn Company Phenyloxazolidinone antimicrobials
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
DE19601265A1 (de) 1996-01-16 1997-07-17 Bayer Ag 2-Oxo- und 2-Thio-1,2-dihydrochinolinyl-oxazolidinone
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19601627A1 (de) 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
GB9601666D0 (en) * 1996-01-27 1996-03-27 Zeneca Ltd Chemical compounds
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
GB9702213D0 (en) * 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
GB9609919D0 (en) 1996-05-11 1996-07-17 Zeneca Ltd Chemical compounds
US6255304B1 (en) 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
ATE293609T1 (de) 1997-05-30 2005-05-15 Upjohn Co Antibakteriell wirksam oxazolidinone mit einer thiocarbonylfunktionalität
DE19730847A1 (de) * 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9717804D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
GB9717807D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
EP1030852B1 (en) * 1997-11-12 2003-09-17 PHARMACIA & UPJOHN COMPANY Oxazolidinone derivatives and pharmaceutical compositions
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
DE19802239A1 (de) * 1998-01-22 1999-07-29 Bayer Ag Neue mit Bicyclen substituierte Oxazolidinone
US7002020B1 (en) 1998-01-23 2006-02-21 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
NZ505902A (en) * 1998-01-23 2003-08-29 Upjohn Co Oxazolidinone compounds useful as antimicrobial agents and combinatorial libraries
US6562844B2 (en) 1998-01-23 2003-05-13 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
US6387896B1 (en) 1999-05-27 2002-05-14 Pharmacia & Upjohn Co. Bicyclic oxazolidinones as antibacterial agents
AU773359B2 (en) 1999-07-28 2004-05-20 Pharmacia & Upjohn Company Oxazolidinones and their use as antiinfectives
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
NZ523700A (en) 2000-07-17 2004-11-26 Ranbaxy Lab Ltd Oxazolidinone derivatives as antimicrobials
DE60121986T2 (de) 2000-10-02 2007-07-26 Emory University Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen
PE20020689A1 (es) 2000-11-17 2002-08-03 Upjohn Co Oxazolidinonas con un heterociclo de 6 o 7 miembros unidos con enlace anular al benceno
US6956040B2 (en) 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
GB0118407D0 (en) * 2001-07-27 2001-09-19 Cipla Ltd Oxazolidinone derivatives as antibacterial agents
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US7012088B2 (en) * 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
AP2007003904A0 (en) * 2004-08-06 2007-02-28 Pharmacia & Upjohn Co Llc Oxazolidinones containing oxindoles as antibacterial agents
SE0402763D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Nitro indazole derivatives
WO2006106426A1 (en) * 2005-04-06 2006-10-12 Pharmacia & Upjohn Company Llc An oxindole oxazolidinone as antibacterial agent
AU2006231919A1 (en) 2005-04-06 2006-10-12 Pharmacia & Upjohn Company Llc 7-fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents
AU2008339607B2 (en) * 2007-12-24 2012-08-02 Cipla Limited Process for the synthesis of propargylated aminoindan derivatives
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES533097A0 (es) * 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
CA1260948A (en) * 1984-12-05 1989-09-26 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents
US4801600A (en) * 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents

Also Published As

Publication number Publication date
TW219936B (lv) 1994-02-01
DE68929303D1 (de) 2001-07-12
JPH1180139A (ja) 1999-03-26
DE68918792T2 (de) 1995-03-30
DK175696B1 (da) 2005-01-24
CA1335103C (en) 1995-04-04
AU617871B2 (en) 1991-12-05
DK45591D0 (da) 1991-03-13
HK1002234A1 (en) 1998-08-07
EP0609905B1 (en) 2001-06-06
JP2865211B2 (ja) 1999-03-08
DK200401246A (da) 2004-08-18
DK175940B1 (da) 2005-08-01
DE68929303T2 (de) 2002-05-02
EP0434714A1 (en) 1991-07-03
ATE112773T1 (de) 1994-10-15
ES2157934T3 (es) 2001-09-01
EP0609905A1 (en) 1994-08-10
DE68918792D1 (de) 1994-11-17
JP3188418B2 (ja) 2001-07-16
EP0359418A1 (en) 1990-03-21
JPH04500665A (ja) 1992-02-06
EP0359418B1 (en) 1994-10-12
KR0138262B1 (ko) 1998-05-15
ATE201870T1 (de) 2001-06-15
AU4195789A (en) 1990-04-02
KR900701780A (ko) 1990-12-04
GR3036491T3 (en) 2001-11-30
WO1990002744A1 (en) 1990-03-22
DK45591A (da) 1991-03-13

Similar Documents

Publication Publication Date Title
LV12888B (lv) 3-(pie slāpekļa atoma aizvietoti)fenil-5-beta-amidometiloksazolidin-2-oni
US5164510A (en) 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
EP1497279B1 (de) Substituierte indole und deren verwendung als 5ht-wiederaufnahme inhibitoren und als 5ht liganden
US5182403A (en) Substituted 3(5'indazolyl) oxazolidin-2-ones
US5225565A (en) Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
CA2411859A1 (en) Novel oxazolidinone derivatives and a process for the preparation thereof
US11685740B2 (en) Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same
KR20010031953A (ko) 옥사졸리디논 유도체 및 제약 조성물
WO2017209265A1 (ja) 二環性複素環誘導体およびそれらを含有する医薬組成物
JP5662940B2 (ja) 新規な抗微生物薬
JP2019182865A (ja) 二環性含窒素複素環誘導体を含有する医薬組成物
EP0500686B1 (en) Tricyclic [6,5,5]/[6,6,5]-fused oxazolidinone antibacterial agents
JP2000229978A (ja) オキサゾリジノン及び抗菌剤としてのそれらの使用
KR101293384B1 (ko) 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
KR20210038632A (ko) 포유류 감염 치료를 위한 신규 화합물
KR100467309B1 (ko) 옥사졸리디논유도체및그의제조방법및항균제조성물
AU2021411868A9 (en) Nrf2-activating compound